Radiotherapy after Neoadjuvant Immunochemotherapy in Unresectable Stage III Non‐Small Cell Lung Carcinoma: A Novel Therapeutic Approach?

作者：Peizhu Wu, Chaozhuo Li, Zhongkai Wei, Xiangjiao Meng · 发表于：Precision Radiation Oncology · 年份：2025 · DOI：10.1002/pro6.70012 · 被引用次数：2 · 研究领域：Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies、Lung Cancer Treatments and Mutations

Neoadjuvant immunochemotherapy provides more surgical opportunities for patients with non-small cell lung carcinoma (NSCLC), especially those with borderline resectable and unresectable tumors. Recently, Zhou et al. reported that neoadjuvant SHR-1701 combined with chemotherapy yielded a post-induction objective response rate of 58% and an 18-month event-free survival (EFS) rate of 56.6% in patients with stage III unresectable NSCLC. Meanwhile, 25% of the patients who underwent surgery conversion across arms achieved R0 resection.1 The tumor was successfully transformed from advanced and inoperable to surgically resectable after treatment with neoadjuvant immunochemotherapy. However, several issues remain unresolved. In this study, the 12-month and 18-month EFS rates were significantly higher in the surgery group than in the radiotherapy group. However, this does not mean that surgical treatment is superior to radiotherapy. The multidisciplinary team selected the surgery group based on patients who had received three cycles of induction therapy, which may have contributed to better treatment outcomes. Radiotherapy may also have beneficial therapeutic effects in patients with favorable outcomes from induction treatment. Randomized controlled clinical trials are needed to validate the therapeutic effects and survival outcomes of surgery and radiotherapy in patients with unresectable NSCLC, which have shown better results after induction immunochemotherapy. Even if patients with ...